Cradle expands its antibody design platform to more argenx teams, where each experiment round sharpens the next design
Synopsis
Cradle announced that argenx, after successful results from initial work, is expanding use of Cradle's end-to-end AI-driven protein engineering platform to more scientists and antibody discovery programs. Previously argenx teams designed from their starting candidates; with the platform, scientists explored sequence space beyond those candidates across successive design, test, and learn rounds and ran designs independently, letting teams test more diverse ideas faster. The platform combines AI-driven engineering, active learning from experimental data, and multi-property optimization in one system, used to optimize existing leads and generate antibody candidates designed for properties including target affinity and selectivity.
Interpretation
argenx is widening use of Cradle's end-to-end AI-driven protein engineering platform from its initial work to more scientists and more antibody discovery programs. The prior condition was argenx using the platform in initial work that produced results both parties describe as successful; the expansion follows that initial work. The expansion rests on those initial results: Cradle says the platform helped argenx optimize existing leads and generate new antibody candidates with designs targeting multiple properties, including target affinity and selectivity.
argenx scientists explored novel sequence space beyond their starting candidates across successive design, test, and learn rounds, and ran designs independently. The starting point was each team's starting candidates; data from each experimental round improved the next round of designs rather than leaving the initial candidate set fixed. This took place within argenx antibody discovery programs, with argenx scientists running designs themselves, which the announcement says let teams test more diverse ideas and move promising designs forward faster.
Perspective
The demonstrated scope is argenx using Cradle's platform in its antibody discovery programs and deciding to widen access to more scientists; the announcement gives no specific program names, targets, or clinical stages.
The announcement describes the initial work as having successful results without disclosing quantitative metrics; what the expanded use will yield is expressed only as looking forward to applying it to more programs.
